03
Dec

Bayer plans to submit its new hemophilia A treatment to regulators by year’s end, following through on a roughly $700 million commitment to roll out next-generation treatments for the bleeding disease.

…read more

Source: Bayer tees up its new hemophilia drug for an FDA submission

    

0 No comments